IRIS Accounts Production v25.1.0.734 Other Company accounts True false Pounds 1.7.23 30.6.24 30.6.24 FY FRS 102 Unaudited Small companies regime for accounts Full Charities SORP true true true false true false true 0 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh090757552023-06-30090757552024-06-30090757552023-07-012024-06-30090757552022-06-30090757552022-07-012023-06-30090757552023-06-3009075755ns0:CharitableCompanyLimitedByGuarantee2023-07-012024-06-3009075755ns15:PoundSterling2023-07-012024-06-3009075755ns11:FRS1022023-07-012024-06-3009075755ns11:AuditExempt-NoAccountantsReport2023-07-012024-06-3009075755ns11:SmallCompaniesRegimeForAccounts2023-07-012024-06-3009075755ns11:FullAccounts2023-07-012024-06-3009075755ns11:CharitiesSORP2023-07-012024-06-3009075755ns16:EnglandWales2023-07-012024-06-3009075755ns11:RegisteredOffice2023-07-012024-06-3009075755ns0:Trustee12023-07-012024-06-3009075755ns0:Trustee22023-07-012024-06-3009075755ns0:Trustee32023-07-012024-06-3009075755ns0:TotalUnrestrictedFunds2023-07-012024-06-3009075755ns0:TotalRestrictedIncomeFunds2023-07-012024-06-3009075755ns0:Activity82023-07-012024-06-3009075755ns0:TotalUnrestrictedFundsns0:Activity82023-07-012024-06-3009075755ns0:Activity8ns0:TotalRestrictedIncomeFunds2023-07-012024-06-3009075755ns0:Activity82022-07-012023-06-3009075755ns0:TotalUnrestrictedFunds2023-06-3009075755ns0:TotalRestrictedIncomeFunds2023-06-3009075755ns0:TotalUnrestrictedFunds2024-06-3009075755ns0:TotalRestrictedIncomeFunds2024-06-3009075755ns0:TotalUnrestrictedFundsns10:WithinOneYear2024-06-3009075755ns10:WithinOneYearns0:TotalRestrictedIncomeFunds2024-06-3009075755ns10:WithinOneYear2024-06-3009075755ns10:WithinOneYear2023-06-3009075755ns10:FurnitureFittingsToolsEquipment2023-07-012024-06-300907575522023-07-012024-06-300907575512023-07-012024-06-300907575512022-07-012023-06-3009075755ns10:OwnedAssets2023-07-012024-06-3009075755ns10:OwnedAssets2022-07-012023-06-3009075755ns0:TotalUnrestrictedFunds2022-07-012023-06-3009075755ns0:TotalRestrictedIncomeFunds2022-07-012023-06-3009075755ns0:TotalUnrestrictedFundsns0:Activity82022-07-012023-06-3009075755ns0:Activity8ns0:TotalRestrictedIncomeFunds2022-07-012023-06-3009075755ns10:FurnitureFittings2023-06-3009075755ns10:FurnitureFittings2023-07-012024-06-3009075755ns10:FurnitureFittings2024-06-3009075755ns10:FurnitureFittings2023-06-30
REGISTERED COMPANY NUMBER: 09075755 (England and Wales)
REGISTERED CHARITY NUMBER: 1162441














REPORT OF THE TRUSTEES AND

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2024

FOR

INDEPENDENT FETAL ANTI-CONVULSANT TRUST

INDEPENDENT FETAL ANTI-CONVULSANT TRUST






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 30 June 2024




Page

Report of the Trustees 1 to 3

Statement of Financial Activities 4

Balance Sheet 5 to 6

Notes to the Financial Statements 7 to 11

INDEPENDENT FETAL ANTI-CONVULSANT TRUST (REGISTERED NUMBER: 09075755)

REPORT OF THE TRUSTEES
for the Year Ended 30 June 2024


The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 30 June 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES
Objectives and aims
The charity's main object is to relieve the needs of disabled persons whose disabilities were caused as a result of their mother taking an anti-convulsant drug during pregnancy to treat her condition in such ways as the trustees may from time to time decide.


INDEPENDENT FETAL ANTI-CONVULSANT TRUST (REGISTERED NUMBER: 09075755)

REPORT OF THE TRUSTEES
for the Year Ended 30 June 2024

ACHIEVEMENT AND PERFORMANCE
This year has been extremely busy with meetings in Westminster with the Patient Safety Commissioner and Health Minister around the possibility for the costings for compensation for those exposed and harmed by Valproate when used in pregnancy.

The year has been one of immense pressure and concentration to ensure those we met understood the position of our members and that we were able to get the main points across when it came to explaining the services and support our members needed to date and for the rest of their lives.

Our first meeting to discuss this took place in August with the Patient Safety Commissioner Dr Henrietta Hughes, we had met with her many times already and she was aware of the problems the families were experiencing, however she was willing to take on board INFACT negotiation costings for compensation and look at how these could be incorporated in her report.

In September, the Medicines and Healthcare products Regulatory Agency (MHRA) met with us to discuss other anti epilepsy medications in pregnancy as they had received research reports about the drug Topiramate having a similar effect in pregnancy. We were very pleased to see the MHRA were listening on this topic and willing to include this medication in their follow up conversations.

The new year began with a very important and successful meeting with Captia, who deals with the details for the Personal Independent Payment for those who are unable to work due to disabilities. Our focus in the meeting was to discuss the time length of the re-assessment asking that those with life long disabilities such as Fetal Valproate Spectrum Disorder be given 10yrs in between re-assessments instead of the anxious wait of 3 years. This was a very good and positive meeting with the outcome being one of success.

As we led up to the publishing of the Patient Safety Commissioners report, the Hughes Report, on the 7th February, the week before was filled with media attention with INFACT giving interviews to LBC Radio with Carole Vordaman joined by former Health Minister Norman Lamb. The following week we met with Epilepsy Research Institute where were gave an interview for their website, and appeared on Newsnight on 6th February where we were interviewed by Victoria Derbyshire concerning the debilitating condition and our hopes for redress. Two weeks later the media continued with ITV Wales interviewing one of our welsh families, BBC Essex speaking to a London family and INFACT having a large piece in the Guardian newspaper.

In May INFACT met with the World Health Organisation to discuss the diagnostic criteria for those affected by other anti-epilepsy medications, especially Topiramate, with the hope of this being recognized enough to receive its diagnostic title on the ICD 11 allowing doctors to recognize it too.

The General election then took place and so work in parliament came to halt, allowing us to give more time and put more emphasis into research and work with our medical advisor Dr Rebecca Bromley towards setting up a diagnostic clinic with funding from the Dept of Health. We were aware this would take some time to establish however there is a lot of work needed leading up to September when we should know more about the possibilities.

We all look forward to the following 12 months and the hope that we finally succeed with the redress that our families so drastically need.

FINANCIAL REVIEW
The statement of financial activities shows a surplus of £12,868 and carried forward funds surplus of £19,047.

Donations during the period were £9,719.

A grant of £20,000 from The Big Lottery Fund - Awards for All was received during the year, with £16,517 outstanding at 30 June 2024.


INDEPENDENT FETAL ANTI-CONVULSANT TRUST (REGISTERED NUMBER: 09075755)

REPORT OF THE TRUSTEES
for the Year Ended 30 June 2024

STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The charity is controlled by its governing document, memorandum and articles of association, and consists a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS
Registered Company number
09075755 (England and Wales)

Registered Charity number
1162441

Registered office
Heather Brae
School Lane
Pilling
Preston
Lancashire
PR3 6AA

Trustees
Mrs J Williams Director
Mrs E Murphy Director
Mrs S Palmer Director

Bankers
Natwest Bank plc
Garstang Branch
Market Place
Garstang
PR3 1ZA

Approved by order of the board of trustees on 11 April 2025 and signed on its behalf by:





Mrs J Williams - Trustee

INDEPENDENT FETAL ANTI-CONVULSANT TRUST

STATEMENT OF FINANCIAL ACTIVITIES
for the Year Ended 30 June 2024

2024 2023
Unrestricted Restricted Total Total
fund fund funds funds
Notes £    £    £    £   
INCOME AND ENDOWMENTS FROM
Donations and legacies 2 2,747 20,000 22,747 19,719

EXPENDITURE ON
Charitable activities
General 1,396 8,483 9,879 13,719

NET INCOME 1,351 11,517 12,868 6,000


RECONCILIATION OF FUNDS
Total funds brought forward 1,179 5,000 6,179 179

TOTAL FUNDS CARRIED FORWARD 2,530 16,517 19,047 6,179

INDEPENDENT FETAL ANTI-CONVULSANT TRUST (REGISTERED NUMBER: 09075755)

BALANCE SHEET
30 June 2024

2024 2023
Unrestricted Restricted Total Total
fund fund funds funds
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 6 937 658 1,595 1,113

CURRENT ASSETS
Cash at bank and in hand 2,052 15,859 17,911 5,463

CREDITORS
Amounts falling due within one year 7 (459 ) - (459 ) (397 )

NET CURRENT ASSETS 1,593 15,859 17,452 5,066

TOTAL ASSETS LESS CURRENT LIABILITIES 2,530 16,517 19,047 6,179

NET ASSETS 2,530 16,517 19,047 6,179
FUNDS 8
Unrestricted funds 2,530 1,179
Restricted funds 16,517 5,000
TOTAL FUNDS 19,047 6,179

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.


The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.


The trustees acknowledge their responsibilities for
(a)ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


INDEPENDENT FETAL ANTI-CONVULSANT TRUST (REGISTERED NUMBER: 09075755)

BALANCE SHEET - continued
30 June 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.


The financial statements were approved by the Board of Trustees and authorised for issue on 11 April 2025 and were signed on its behalf by:





Mrs J Williams - Trustee

INDEPENDENT FETAL ANTI-CONVULSANT TRUST

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 30 June 2024

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.


Fixtures and fittings - 15% on reducing balance

TAXATION
The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

The total funds of the charity are unrestricted.

2. DONATIONS AND LEGACIES
2024 2023
£    £   
Donations 2,747 9,719
Grants 20,000 10,000
22,747 19,719

Grants received, included in the above, are as follows:

2024 2023
£    £   
The Big Lottery Fund - Award for All 20,000 10,000

INDEPENDENT FETAL ANTI-CONVULSANT TRUST

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 June 2024

3. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

2024 2023
£    £   
Depreciation - owned assets 176 196

4. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 June 2024 nor for the year ended 30 June 2023.


TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 30 June 2024 nor for the year ended 30 June 2023.


5. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
Unrestricted Restricted Total
fund fund funds
£    £    £   
INCOME AND ENDOWMENTS FROM
Donations and legacies 9,719 10,000 19,719

EXPENDITURE ON
Charitable activities
General 8,719 5,000 13,719

NET INCOME 1,000 5,000 6,000


RECONCILIATION OF FUNDS
Total funds brought forward 179 - 179

TOTAL FUNDS CARRIED FORWARD 1,179 5,000 6,179


INDEPENDENT FETAL ANTI-CONVULSANT TRUST

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 June 2024

6. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 1 July 2023 2,730
Additions 658
At 30 June 2024 3,388
DEPRECIATION
At 1 July 2023 1,617
Charge for year 176
At 30 June 2024 1,793
NET BOOK VALUE
At 30 June 2024 1,595
At 30 June 2023 1,113

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Accruals and deferred income 459 397

8. MOVEMENT IN FUNDS
Net
movement At
At 1/7/23 in funds 30/6/24
£    £    £   
Unrestricted funds
General fund 1,179 1,351 2,530

Restricted funds
The Big Lottery Fund - Awards for All 5,000 11,517 16,517

TOTAL FUNDS 6,179 12,868 19,047

INDEPENDENT FETAL ANTI-CONVULSANT TRUST

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 June 2024

8. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£    £    £   
Unrestricted funds
General fund 2,747 (1,396 ) 1,351

Restricted funds
The Big Lottery Fund - Awards for All 20,000 (8,483 ) 11,517

TOTAL FUNDS 22,747 (9,879 ) 12,868


Comparatives for movement in funds

Net
movement At
At 1/7/22 in funds 30/6/23
£    £    £   
Unrestricted funds
General fund 179 1,000 1,179

Restricted funds
The Big Lottery Fund - Awards for All - 5,000 5,000

TOTAL FUNDS 179 6,000 6,179

Comparative net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£    £    £   
Unrestricted funds
General fund 9,719 (8,719 ) 1,000

Restricted funds
The Big Lottery Fund - Awards for All 10,000 (5,000 ) 5,000

TOTAL FUNDS 19,719 (13,719 ) 6,000

INDEPENDENT FETAL ANTI-CONVULSANT TRUST

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 June 2024

8. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

Net
movement At
At 1/7/22 in funds 30/6/24
£    £    £   
Unrestricted funds
General fund 179 2,351 2,530

Restricted funds
The Big Lottery Fund - Awards for All - 16,517 16,517

TOTAL FUNDS 179 18,868 19,047

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£    £    £   
Unrestricted funds
General fund 12,466 (10,115 ) 2,351

Restricted funds
The Big Lottery Fund - Awards for All 30,000 (13,483 ) 16,517

TOTAL FUNDS 42,466 (23,598 ) 18,868

The Big Lottery Fund - Awards for All

The Big Lottery Fund awarded £20,000 to Independent Fetal Anti-Convulsant Trust in order to cover costs of running the charity. The funding should be allocated as £1,000 for room hire, £3,000 for travel costs, £2,500 for advertising costs, £6,000 for conference organisation, £4,000 for accomodation, £500 for website updates, £1,000 for stationary and £2,000 for equipment.

9. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 June 2024.